

Special Issue

Targeting Blood Vessel Components to Treat Cancer

Message from the Guest Editors

Most current research studies have demonstrated that the direct crosstalk between tumor stromal cells and between stromal and malignant cells can control cancer growth and sensitivity to therapy. Although tumor blood vessels are routes for the delivery of oxygen and nutrients to tumors, immunosuppressive functions or angiocrine signals have been described to be involved in tumor growth and chemoresistance. This Special Issue of *Cancers* aims to collect a series of comprehensive reviews and studies describing original aspects regarding new roles of blood vessels in tumor growth. Investigations in the fields of chemotherapy, immune antitumor responses, immunotherapy (therapeutic options and mechanisms or resistance/sensitization mediated by changes in tumor blood vessels) are topics of special interest to this issue.
Dr. Jose M. Munoz-Felix

Guest Editors

Prof. Kairbaan Hodivala-Dilke

Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK

Dr. José M. Muñoz-Félix

Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, 37007 Salamanca, Spain

Deadline for manuscript submissions

closed (30 September 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/40507

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)